ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
62 905,89
-1,31%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Sangamo Therapeutics Inc (SGMO)

  7. Sangamo Therapeutics Inc (SGMO) Actualités

SGMO Sangamo Therapeutics Inc

0,5101
0,0071 (1,41%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Sangamo Therapeutics Inc SGMO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0071 1,41% 0,5101 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,52 0,503 0,5339 0,5178 0,503
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
22/4/202422:35BWSangamo Therapeutics to Present Neurology-Focused..
22/3/202413:05BWSangamo Therapeutics Announces Pricing of $24.0 Million..
13/3/202413:05BWSangamo Therapeutics Reports Recent Business Highlights and..
13/3/202413:01BWSangamo Therapeutics Announces Data From Novel Proprietary..
12/3/202423:30BWSangamo Therapeutics Announces Fourth Quarter and Full Year..
27/2/202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202423:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202423:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202423:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202414:05BWSangamo Therapeutics Announces U.S. FDA Alignment on..
06/2/202422:35EDGAR2Form 8-K - Current report
06/2/202400:01BWSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study..
26/1/202417:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/1/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202423:09EDGAR2Form 8-K - Current report
13/12/202313:55EDGAR2Form 8-K - Current report
28/11/202322:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202321:02EDGAR2Form 8-K - Current report
01/11/202321:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202321:02EDGAR2Form 8-K - Current report
01/11/202321:01BWSangamo Therapeutics Announces Strategic Update and Reports..
25/10/202322:15BWSangamo Therapeutics Announces Third Quarter 2023 Conference..
24/10/202308:01BWSangamo Therapeutics to Present Pre-Clinical Data Showcasing..
20/9/202322:15BWSangamo Therapeutics to Present at the Jefferies Cell &..
29/8/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202322:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202322:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202322:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/8/202322:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202322:47EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/8/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:08EDGAR2Form 8-K - Current report
08/8/202322:01BWSangamo Therapeutics Reports Recent Business Highlights and..
01/8/202322:15BWSangamo Therapeutics Announces Second Quarter 2023..
20/7/202314:05BWSangamo Therapeutics and Chroma Medicine Announce Option and..
17/7/202314:05BWSangamo Therapeutics Announces Research Evaluation and..
29/6/202314:05BWSangamo Therapeutics and Voyager Therapeutics Enter License..

Dernières Valeurs Consultées

NASDAQ
SGMO
Sangamo Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés